Immunomodulation in allergic rhinitis: Insights from Th2 cells and NLRP3/IL-18 pathway
- PMID: 38555506
- DOI: 10.1002/cbf.3997
Immunomodulation in allergic rhinitis: Insights from Th2 cells and NLRP3/IL-18 pathway
Abstract
Allergic rhinitis (AR) is characterized by nasal symptoms such as rubbing and sneezing, often triggered by allergen exposure. The purpose of this study is to dissect the roles of NLRP3-mediated immune modulation and macrophage pyroptosis in modulating T cell differentiation within the context of ovalbumin (OVA)-induced AR in mice. OVA-induced AR was established in mice, evaluating nasal symptoms, macrophage infiltration, cytokine levels, and T cell differentiation. Manipulations using NLRP3-/-, ASC-/- mice, clodronate liposome treatment, and NLRP3 inhibitor MCC950 were performed to assess their impact on AR symptoms and immune responses. Following OVA stimulation, increased nasal symptoms were observed in the OVA group along with augmented GATA3 expression and elevated IL-4 and IL-1b levels, indicative of Th2 polarization and cellular pyroptosis involvement. NLRP3-/- and ASC-/- mice exhibited reduced CD3+ T cells post OVA induction, implicating cellular pyroptosis in AR. Macrophage depletion led to decreased IgE levels, highlighting their involvement in allergic responses. Further investigations revealed enhanced macrophage pyroptosis, influencing Th1/Th2 differentiation in AR models. IL-18 released through NLRP3-mediated pyroptosis induced Th2 differentiation, distinct from IL-1b. Additionally, MCC950 effectively mitigated AR symptoms by modulating Th2 responses and reducing macrophage infiltration. This comprehensive study unravels the pivotal role of NLRP3-mediated immune modulation and macrophage pyroptosis in Th1/Th2 balance regulation in OVA-induced AR. Targeting NLRP3 pathways with MCC950 emerged as a promising strategy to alleviate AR symptoms, providing insights for potential therapeutic interventions in AR management.
Keywords: IgE; NLRP3; Th2 cells; allergic rhinitis; macrophage; ovalbumin.
© 2024 John Wiley & Sons Ltd.
Similar articles
-
Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model.Int Immunopharmacol. 2020 Jun;83:106394. doi: 10.1016/j.intimp.2020.106394. Epub 2020 Mar 16. Int Immunopharmacol. 2020. PMID: 32193102
-
Long non-coding RNA NEAT1 exacerbates NLRP3-mediated pyroptosis in allergic rhinitis through regulating the PTBP1/FOXP1 cascade.Int Immunopharmacol. 2024 Aug 20;137:112337. doi: 10.1016/j.intimp.2024.112337. Epub 2024 Jun 10. Int Immunopharmacol. 2024. PMID: 38861915
-
Activation of NLRP3 inflammasome contributes to the inflammatory response to allergic rhinitis via macrophage pyroptosis.Int Immunopharmacol. 2022 Sep;110:109012. doi: 10.1016/j.intimp.2022.109012. Epub 2022 Jul 6. Int Immunopharmacol. 2022. PMID: 35809382
-
Pathogenesis and Key Cells in Allergic Rhinitis.Int Arch Allergy Immunol. 2025;186(5):418-429. doi: 10.1159/000541666. Epub 2024 Nov 19. Int Arch Allergy Immunol. 2025. PMID: 39561729 Review.
-
Group 2 Innate Lymphoid Cells in Allergic Rhinitis.J Inflamm Res. 2024 Nov 9;17:8599-8610. doi: 10.2147/JIR.S485128. eCollection 2024. J Inflamm Res. 2024. PMID: 39539728 Free PMC article. Review.
Cited by
-
Correlation and diagnostic significance of CD4 T cell subsets and NLRP3 inflammasome in ulcerative colitis: the role of the NLRP3/T-bet/GATA3 axis.BMC Gastroenterol. 2025 Jan 21;25(1):23. doi: 10.1186/s12876-025-03603-w. BMC Gastroenterol. 2025. PMID: 39833691 Free PMC article.
-
Use of bidirectional Mendelian randomization to unveil the association between antibody-mediated immune responses to infectious agents and allergic rhinitis.Hum Vaccin Immunother. 2025 Dec;21(1):2523090. doi: 10.1080/21645515.2025.2523090. Epub 2025 Jul 8. Hum Vaccin Immunother. 2025. PMID: 40625166 Free PMC article. Review.
-
IL-18 favors Th2 responses in sporotrichosis caused by Sporothrix globosa, prolonging the course of the disease.PLoS Negl Trop Dis. 2025 Jun 9;19(6):e0013170. doi: 10.1371/journal.pntd.0013170. eCollection 2025 Jun. PLoS Negl Trop Dis. 2025. PMID: 40489556 Free PMC article.
-
Unraveling the role of NLRP3 inflammasome in allergic inflammation: implications for novel therapies.Front Immunol. 2024 Jul 26;15:1435892. doi: 10.3389/fimmu.2024.1435892. eCollection 2024. Front Immunol. 2024. PMID: 39131161 Free PMC article. Review.
-
The NLRP3 inflammasome in allergic diseases: mechanisms and therapeutic implications.Clin Exp Med. 2024 Sep 26;24(1):231. doi: 10.1007/s10238-024-01492-z. Clin Exp Med. 2024. PMID: 39325206 Free PMC article. Review.
References
REFERENCES
-
- Siddiqui Z, Walker A, Pirwani M, Tahiri M, Syed I. Allergic rhinitis: diagnosis and management. Br J Hosp Med. 2022;83(2):1‐9.
-
- Hoyte FCL, Nelson HS. Recent advances in allergic rhinitis. F1000Res. 2018;7:(F1000 Faculty Rev):1333. doi:10.12688/f1000research.15367
-
- Bousquet J, Anto JM, Bachert C, et al. Allergic rhinitis. Nat Rev Dis Primers. 2020;6(1):95.
-
- Wise SK, Damask C, Roland LT, et al. International consensus statement on allergy and rhinology: allergic rhinitis − 2023. Int Forum Allergy Rhinol. 2023;13(4):293‐859.
-
- Bayar Muluk N, Bafaqeeh SA, Cingi C. Anti‐IgE treatment in allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2019;127:109674.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous